Clinical data | |
---|---|
Trade names | Vimpat |
Other names | (2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide |
AHFS/Drugs.com | Monograph |
MedlinePlus | a609028 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth, intravenous |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | High |
Elimination half-life | 13 hours |
Excretion | Kidney |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.112.805 |
Chemical and physical data | |
Formula | C13H18N2O3 |
Molar mass | 250.298 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Lacosamide, sold under the brand name Vimpat among others, is a medication used for the treatment of partial-onset seizures and primary generalized tonic-clonic seizures.[2] It is used by mouth or intravenously.[2]
It is available as a generic medication.[4][5]